Principia Wealth Advisory, LLC Eye Point Pharmaceuticals, Inc. Call Options Transaction History
Principia Wealth Advisory, LLC
- $104 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EYPT
# of Institutions
157Shares Held
72.7MCall Options Held
187KPut Options Held
225K-
Cormorant Asset Management, LP Boston, MA8.33MShares$48.5 Million4.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.78MShares$39.5 Million2.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.75MShares$33.5 Million0.08% of portfolio
-
Franklin Resources Inc San Mateo, CA4.14MShares$24.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.8MShares$22.2 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $199M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...